Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006–2007 and 2012–2013

BMC Oral Health

Kazumasa Sugihara¹  Tomofumi Hamada¹  Ryoichi Sakamoto¹  Daisuke Hirabayashi¹  Junichi Fujisaki¹  Tomohiro Nagayama¹  Youichirou Mori¹  Yoshiaki Kamikawa² 

[1] Field of Maxillofacial Diagnostic and Surgical Science, Department of Oral and Maxillofacial Rehabilitation, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan;Department of Oral Surgery, Kagoshima University Medical and Dental Hospital, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan

关键词: Resistant strains;    Minimal inhibitory concentration;    Clinically isolated strains;    Candida albicans;    Candida glabrata;   

Others  :  1121456
DOI  :  10.1186/1472-6831-14-14

 received in 2013-12-15, accepted in 2014-02-12,  发布年份 2014

【 摘 要 】

Background

The isolation frequency and susceptibility to antifungal agents of oral Candida isolates from patients with oral candidiasis (OC) were compared between studies conducted in 2006–2007 and 2012–2013.

Methods

A total158 strains was isolated from 112 patients who visited Kagoshima University Hospital for the treatment of OC during the 14-month period from February 2012 and March 2013, and evaluated on the isolation frequency of each Candida strain and the susceptibility against antifungal drugs as compared to those evaluated in 2006–2007.

Results

There was a higher frequency of xerostomia as a chief complaint and of autoimmune disease in the 2012–2013 study than in the 2006–2007 study. More than 95% of Candida isolates were C. albicans and C. glabrata. In addition, the proportion of the latter increased from 12.3% in the 2006–2007 study to 23.4% in the 2012–2013 study, while the proportion of the former decreased from 86.2% to 72.8%, respectively. C. albicans was isolated in almost all patients, while C. glabrata was only isolated concomitantly with C. albicans. Minimal inhibitory concentrations (MICs) were not significantly different between groups with a few exceptions. Candida isolates, of which MICs surpassed break points, apparently increased for miconazole and itraconazole against C. glabrata in the 2012–2013 study, but this was not statistically significant. As a result, more cases of autoimmune disease, a greater number of C. glabrata isolates, and higher resistance to azoles were seen in the 2012–2013 study than in the 2006–2007 study.

Conclusion

These data indicate that with recent increases in C. glabrata infection, a causative fungus of OC, and in C. glabrata resistance to azoles, caution is needed in the selection of antifungal drugs for the treatment of OC.

【 授权许可】

   
2014 Kamikawa et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA: International surveillance of blood stream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and south america for the SENTRY program. The SENTRY participant group. J Clin Microbiol 1997, 36:1886-1889.
• [2]Messer SA, Moet GJ, Kirby JT, Jones RN: Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and aspergillus spp.: report from the SENTRY antimicrobial surveillance program (2006 to 2007). J Clin Microbiol 2009, 47:1942-1946.
• [3]Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001, 33:1529-1535.
• [4]Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, Smietana JM, DiNubile MJ, Sable CA: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002, 113:294-299.
• [5]de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M, Diekmann-Berndt H: A randomized, double blind, parallel group, dose–response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV positive patients. Clin Infect Dis 2004, 39:842-8499.
• [6]Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, Aible M, Henkel T: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004, 39:770-775.
• [7]Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S, the Japan invasive mycosis surveillance study group: National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 2004, 53:283-289.
• [8]Yamaguchi H, Uchida K, Okuzumi K, Oguri T, Adachi K, Kawakami S, Tosaka M, Kawashima C, Hori Y, Kitazawa T, Hayamshi M, Saito Y, Ozaki K, Nishiyama Y: Nationwide survey of antifungal drug susceptibility of clinical fungal isolates in Japan for the Japan antifungal surveillance program (JASP), 2001–2002. J Jpn Soc Clin Microbiol 2004, 14:183-193.
• [9]Yamaguchi H, Uchida K, Nishiyama Y, Okuizumi K, Oguri T, Adachi K, Kawakami S, Tosaka M, Misawa Y, Kawashima C, Hori Y, Kitazawa T, Hayashi M, Okimura Y: Nationwide survey of antifungal drug susceptibility of clinical fungal isolates in Japan for the Japan antifungal surveillance program (JASP), 2003. J Jpn Soc Clin Microbiol 2006, 16:13-22.
• [10]Yamaguchi H, Nishiyama Y, Uchida K, Takahashi C, Kawashima C, Hayashi M, Kawakami S, Adachi K, Okuizumi K, Misawa Y, Oguri T, Okimura Y, Kitazawa T, Hori Y, Tosaka M: Nationwide survey of antifungal drug susceptibility of clinical fungal isolates in Japan for the Japan antifungal surveillance program (JASP), 2005. J Jpn Soc Clin Microbiol 2009, 19:128-141.
• [11]Kamikawa Y, Nagayama T, Fujisaki J, Hirabayashi D, Kawasaki K, Hamada T, Mori Y, Kamikawa Y, Mukai H, Sato T, Sugihara K: Clinical study on anti-fungal drug activity against clinically isolated strains of oral Candida species. Oral Sci Int 2013, 10:87-94.
• [12]Sudo T, Makimura K, Kawata K, Ito A, Oka S, Uchida K, Yamaguchi H: Evaluation of antifungal susceptibility testing by the broth micro dilution method against Candida species: activities of 5 antifungal agents against Candida species isolated from oral candidiasis or other candidal infectious diseases and correlation of vitro data and clinical outcome of fluconazole therapy. Jpn J Chemotherapy 1997, 45:115-122.
• [13]Kanbe T, Horii T, Arishima T, Ozeki M, Kikuchi A: PCR-based identification of pathogenic Candida species using primer mixes specific to Candida DNA topoisomerase II genes. Yeast 2002, 19:973-989.
• [14]Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD: Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis 2009, 48:503-535.
• [15]Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard-third edition M27-A3. Wayne PA USA: CLSI; 2008.
• [16]Yamaguchi H: Anti-fungal drug sensitivity test. Modern media 2009, 55:309-320.
• [17]Asmundsdottir LR, Erlendsdottir H, Gottfredsson M: Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011. J Clin Microbiol 2013, 51:841-848.
• [18]de Almeida AA, Mesquita CSS, Svidzinski TIES, de Oliveira KMP: Antifungal susceptibility and distribution of Candida spp. Isolates from the university hospital in the municipality of Dourados, state of Mato Grosso do Sul, Brazil. Rev Soc Bras Med Trop 2013, 46:335-339.
• [19]De luca C, Guglielminetti M, Ferrario A, Calabrὸ M, Casari E: Candidemia: species involved, virulence factors and antimycotic susceptibility. New Microbiol 2012, 35:459-468.
• [20]Santhanam J, Yahaya N, Aziz MN: Species distribution and antifungal susceptibility patters of Candida species: is low susceptibility to itaconazole a trend in Malaysia? Med J Mlaysia 2013, 68:343-347.
• [21]Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D: Epidemiology and outcomes of candidemia in 3648 patients: data from the prospective antifungal therapy (PATH alliance®) registry, 2004–2008. Diagn Microbiol Infect Dis 2012, 74:323-331.
• [22]Moretti ML, Trabasso P, Lyra L, Fagnani R, Resende MR, de Oliveira Cardoso LG, Schreiber AZ: Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil. Med Mycol 2013, 51:225-230.
• [23]Zhang XB, Yu SJ, Yu JX, Gong YL, Feng W, Sun FJ: Retrospective analysis of epidemiology and prognostic factors for candidemia at a hospital in China, 2000–2009. Jpn J Infect Dis 2012, 65:510-515.
• [24]Hoegl L, Thoma-Greber E, Röcken M, Korting HC: Persistent oral candidosis by non-albicans Candida strains including Candida glabrata in a human immunodeficiency cirus-infected patient observed over a period of 6 years. Mycoses 1998, 41:335-338.
• [25]Redding SW, Kirkpatrick WR, Coco BJ, Sadkowski L, Fothergill AW, Rinaldi MG, Eng TY, Patterson TF: Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J Clin Micribiol 2002, 40:1879-1881.
• [26]Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP: Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 2002, 35:627-630.
• [27]Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL: The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996, 100:617-623.
• [28]Pfaller AM, Jones RN, Messer SA, Edmond MB, Wenzel RP: National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program. Diag Microbiol Infect Dis 1998, 30:121-129.
• [29]Silva S, Henriques M, Hayes A, Oliveira R, Azeredo J: Candida glabrata and Candida albicans co-infection of an in vitro oral epithelium. Oral Pathol Med 2011, 40:421-427.
• [30]Meurman JH, Siikala E, Richardson M, Rauteman R: Non-Candia albicans Candida yeasts of the oral cavity. Communicating current research and educational topics and trends in applied microbiology. Madrid: Formatex; 2007:719-731.
• [31]Sanita PV, de Oliveira Mima EG, Pavarina AC, Jorge JH, Machando AL, Vergani CE: Susceptibility profile of a Brazilian yeast stock collection of Candida species isolated form subjects with Candida-associated denture stomatitis with or without diabetes. Oral Surg Oral Med Oral Pathol Oral Radiol 2013, 116:562-569.